Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been fully informed about the study and have signed and dated a consent form before the study begins
• People who are able and willing to attend all required visits and follow the study procedures
• People aged between 18 and 75 years
• People whose general health and ability to carry out daily activities meets a standard rating of 0 or 1 on a scale used by doctors to measure cancer patients' wellbeing (confirm with trial site)
• People who have either already received standard treatment for their cancer that has spread to other parts of the body, or who have not yet been treated for cancer that has spread
• People whose organs (such as liver and kidneys) and bone marrow are functioning well enough to meet the study's requirements
• People who have at least one measurable tumour outside the brain that can be tracked during the study
• People who have suitable stored tissue samples from a previous biopsy available for testing

Who may not be able to join:

• People who have previously received any drug treatment specifically targeting a protein called HER3, including antibodies, antibody-drug conjugates, or CAR-T cell therapy
• People who have previously had a serious reaction to or could not tolerate a type of chemotherapy called topoisomerase I inhibitors, or treatments that contain them
• People who are currently taking part in another clinical trial that involves an active treatment (being in a follow-up period or an observation-only study may be acceptable — confirm with trial site)
• People who have not waited long enough since their last cancer treatment before starting this study (confirm with trial site)
• People who have had major surgery (not including diagnostic procedures) within 4 weeks before starting the study, or who are expected to need major surgery during the study
• People who have previously had a bone marrow transplant using donor cells, or a transplant of a solid organ
• People who have taken steroid medications above a certain dose, or other immune-suppressing medicines, within 2 weeks before starting the study
• People who have received a live vaccine within 4 weeks before starting the study, or who plan to receive one during the study
• People whose cancer has spread to the membranes surrounding the brain or spinal cord
• People who have cancer that has spread to the brain, or who have compression of the spinal cord
• People with serious heart or blood vessel conditions that are not under control
• People with significant or complicated lung conditions
• People who have been diagnosed with a liver condition called Gilbert syndrome
• People with a build-up of fluid in body cavities that cannot be controlled and requires repeated draining
• People who have had a bowel perforation or abnormal passage (fistula) within 6 months before starting the study, or who have active stomach or bowel ulcers or other digestive conditions that may increase the risk of bleeding or perforation
• People who have a serious active infection at the time of starting the study
• People with a known HIV infection
• People with active hepatitis B or hepatitis C infection
• People who have had another type of cancer within the past 5 years before starting the study
• People who still have unresolved side effects from previous cancer treatments
• People with a history of severe allergic reactions to ingredients in the study drug or to similar types of medicines (monoclonal antibodies)
• Women who are pregnant or breastfeeding
• People with conditions — including mental health conditions or substance or alcohol misuse — that the study doctor believes would interfere with their ability to safely participate or to give informed consent

Important: Always verify eligibility with the trial site directly before applying.